pembrolizumab


( Last Updated : April 14, 2021)
Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
Esophageal carcinoma, gastroesophageal junction adenocarcinoma
Manufacturer:
Merck Canada
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0250-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
​First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openApril 14, 2021
Call for patient/clinician input closedJune 04, 2021
Clarification:

- Patient input submission received from Colorectal Cancer Canada, Gastrointestinal Society, and My Gut Feeling - Stomach Cancer Foundation of Canada.

Submission receivedMay 26, 2021
Submission acceptedJune 09, 2021
Review initiatedJune 10, 2021
Draft CADTH review report(s) provided to sponsor for commentAugust 25, 2021
Deadline for sponsors commentsSeptember 03, 2021
CADTH responses on draft review report(s) provided to sponsorOctober 07, 2021
Expert committee meeting (initial)October 20, 2021
Draft recommendation issued to sponsorNovember 01, 2021
To
November 03, 2021